🦠
MicroDAO Whitepaper
  • MICRO: Funding the next generation of AMR Solutions: Antimicrobials, Diagnostics, and Vaccines
    • Executive Summary
    • The AMR Challenge
      • Understanding Antimicrobial Resistance
      • The Human Innovation Gap
      • Investments into AMR solutions
    • microDAO: A Community-Driven Solution to Tackle AMR
      • Vision and Mission
      • Operational Framework
      • Structure of microDAO
        • Core Team
        • Community Members
        • Token Holders
        • Working Groups
        • Service Providers
        • Partners
        • End users of solutions and funding offered by microDAO
    • DAO Way of Working
    • microDAO’s Flywheel for Impact and Revenue: Community Tools and Workflows
      • Evidence Generation & Decision Support Tools
      • R&D Acceleration Tools
    • microDAO Revenue Streams: Building Sustainable Impact
    • Fund Allocation Strategy for liquid funds available in the DAO treasury
      • Strategic Priority Areas
        • Early-Stage Research Development
        • Clinical Development Support
        • Equitable Access Programmes
        • Infrastructure and Tools
        • Operational Sustainability
    • Impact and Future Outlook
Powered by GitBook
On this page
  1. MICRO: Funding the next generation of AMR Solutions: Antimicrobials, Diagnostics, and Vaccines

Fund Allocation Strategy for liquid funds available in the DAO treasury

MicroDAO's fund allocation strategy aims to maximise its impact in combating antimicrobial resistance (AMR) while ensuring operational sustainability. Our model focuses on addressing critical gaps in the AMR research and development pipeline, with particular emphasis on early-stage projects and equitable access.

PreviousmicroDAO Revenue Streams: Building Sustainable ImpactNextStrategic Priority Areas

Last updated 6 months ago